Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» GlaxoSmithKline eyes Pfizer's OTC unit. But will a buy imperil its dividend?
GlaxoSmithKline eyes Pfizer's OTC unit. But will a buy imperil its dividend?
GlaxoSmithKline eyes Pfizer's OTC unit. But will a buy imperil its dividend?
Submitted by
admin
on October 25, 2017 - 10:13pm
Source:
Fierce Pharma
News Tags:
GSK
M&A
Pfizer
OTC
consumer health
Headline:
GlaxoSmithKline eyes Pfizer's OTC unit. But will a buy imperil its dividend?
Do Not Allow Advertisers to Use My Personal information
